Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
Aevi Genomic Medicine is focused on translating genetic discoveries into novel the...
Aevi Genomic Medicine is focused on translating...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
Join the National Investor Network and get the latest information with your interests in mind.